Idasanutlin Active in Refractory Polycythemia Vera

More data out of the 2017 American Society of Hematology Annual Meeting shows that the MDM2 antagonist idasanutlin is well tolerated and demonstrates clinical activity among patients with refractory polycythemia vera.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.